Kamada (KMDA) Cash & Equivalents (2012 - 2026)
Kamada's (KMDA) quarterly Cash & Equivalents came in at $29.5 million in Q2 2026, down 55.33% on a YoY basis from $66.0 million in Q2 2025, and down 10.48% quarter-over-quarter from $32.9 million in Q1 2026.
Analysis
Kamada (KMDA) Cash & Equivalents (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Cash & Equivalents for 15 consecutive years, with $29.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Equivalents fell 55.33% year-over-year to $29.5 million; the trailing twelve-month figure through Jun 2026 stood at $29.5 million (down 55.33% YoY), and the FY2025 full-year result was $75.5 million, down 3.78% from the prior year.
- Cash & Equivalents eased to $29.5 million in Q2 2026 per KMDA's latest filing, from $32.9 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $78.4 million in Q4 2024 and bottomed at $29933.0 in Q2 2022.
- Historically, Cash & Equivalents has averaged $47.3 million across 5 years, with a median of $50.4 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 99.96% in 2022, then jumped 72689.23% in 2023.
- Over 5 years, Cash & Equivalents stood at $34.3 million in 2022, then soared by 62.42% to $55.6 million in 2023, then soared by 40.97% to $78.4 million in 2024, then declined by 3.78% to $75.5 million in 2025, then plunged by 60.95% to $29.5 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $29.5 million, $32.9 million, and $75.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.14 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 2.46 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 3.58 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 1.72 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.71 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.25 Bn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 29.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.47 Mn |
| Mar 31, 2026 | 32.92 Mn |
| Dec 31, 2025 | 75.47 Mn |
| Sep 30, 2025 | 72.00 Mn |
| Jun 30, 2025 | 65.99 Mn |
| Mar 31, 2025 | 76.25 Mn |
| Dec 31, 2024 | 78.44 Mn |
| Sep 30, 2024 | 72.00 Mn |
| Jun 30, 2024 | 56.55 Mn |
| Mar 31, 2024 | 48.19 Mn |
| Dec 31, 2023 | 55.64 Mn |
| Sep 30, 2023 | 52.60 Mn |
| Jun 30, 2023 | 21.79 Mn |
| Mar 31, 2023 | 27.12 Mn |
| Dec 31, 2022 | 34.26 Mn |
| Sep 30, 2022 | 31.25 Mn |
| Jun 30, 2022 | 29,933.00 |
| Mar 31, 2022 | 21.97 Mn |
| Dec 31, 2021 | 18.59 Mn |
| Sep 30, 2021 | 99.84 Mn |